Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2008-07-22
2008-07-22
Landsman, Robert (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S300000
Reexamination Certificate
active
07402658
ABSTRACT:
Novel receptor in the TNF family: TRAIN-receptor.
REFERENCES:
patent: 5225538 (1993-07-01), Capon et al.
patent: 2002/0068696 (2002-06-01), Wood et al.
patent: 2003/0027272 (2003-02-01), Baker et al.
patent: 2003/0219860 (2003-11-01), Tschopp et al.
patent: 2004/0142423 (2004-07-01), Tada et al.
patent: 2006/0058223 (2006-03-01), Mi et al.
patent: 0 990 703 (2000-04-01), None
patent: WO 94/04679 (1994-03-01), None
patent: WO 98/01554 (1998-01-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/13078 (1999-03-01), None
patent: WO 99/20644 (1999-04-01), None
patent: WO 99/33967 (1999-07-01), None
patent: WO 99/33980 (1999-07-01), None
patent: WO 99/37818 (1999-07-01), None
patent: WO 00/01817 (2000-01-01), None
patent: WO 00/49149 (2000-08-01), None
patent: WO 00/53758 (2000-09-01), None
patent: WO 01/38526 (2001-05-01), None
patent: WO 01/58954 (2001-08-01), None
patent: WO 01/68848 (2001-09-01), None
patent: WO 01/93983 (2001-12-01), None
patent: WO 02/00690 (2002-01-01), None
patent: WO 02/08284 (2002-01-01), None
patent: WO 02/08288 (2002-01-01), None
patent: WO 03/013578 (2003-02-01), None
patent: WO 2005/058028 (2005-06-01), None
patent: WO 2006/017673 (2006-02-01), None
Banner, D.W., et al., “Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNFβ Complex: Implications for TNF Receptor Activation,”Cell 73:431-445, Cell Press (1993).
Bodmer, J.L., et al., “The molecular architecture of the TNF superfamily,”Trends Biomed. Sci. 27:19-26, Elevier Science Ltd. (Jan. 2002).
Eby, M.T., et al., “TAJ, a Novel Member of the Tumor Necrosis Factor Receptor Family, Activates the c-Jun N-terminal Kinase Pathway and Mediates Caspase-independent Cell Death,”J. Biol. Chem. 275:15336-15342, The American Society for Biochemistry and Molecular Biology, Inc. (May 2000).
Hisaoka, T., et al., “Expression of a member of tumor necrosis factor receptor superfamily, TROY, in the developing mouse brain,”Develop. Brain Res. 143:105-109, Elsevier Science B.V. (Jun. 2003).
Kojima, T., et al., “TROY, A Newly Identified Member of the Tumor Necrosis Factor Receptor Superfamily, Exhibits a Homology with Edar and Is Expressed in Embryonic Skin and Hair Follicles,”J. Biol. Chem. 275:20742-20747, The American Society for Biochemistry and Molecular Biology, Inc. (Jul. 2000).
Mandemakers, W.J. and Barres B.A., “Axon Regeneration: It's Getting Crowded at the Gates of TROY,”Curr. Biol. 15: R302-R305, Cell Press (Apr. 2005).
Robertson, N.G., et al., “Isolation of Novel and Known Genes from a Human Fetal Cochlear cDNA Library Using Subtractive Hybridization and Differential Screening,”Genomics 23:42-50, Academic Press, Inc. (1994).
Shao, Z., et al., “TAJ/TROY, an Orphan TNF Receptor Family Member, Binds Nogo-66 Receptor 1 and Regulates Axonal Regeneration,”Neuron 45:353-359, Elsevier Inc. (Feb. 2005).
Wang, Y., et al., “An Alternative Form of Paraptosis-Like Cell Death, Triggered by TAJ/TROY and Enhanced by PDCD5 Overexpression,”J. Cell Sci. 117:1525-1532, The Company of Biologists (Mar. 2004).
Wilson, C.A., et al. “Death of HT29 adenocarcinoma cells induced by TNF family receptor activation is caspase-independent and displays features of both apoptosis and necrosis,”Cell Death Diff. 9:1321-1333, Nature Publishing Group (Dec. 2002).
NCBI Entrez, Accession No. AAF71828, Eby, M.T., et al. (May 25, 2000).
NCBI Entrez, Accession No. NP—061117, Clark, H.F., et al. (Jul. 5, 2000).
NCBI Entrez, Accession No. BAB03269, Kojima, T., et al. (Jul. 22, 2000).
NCBI Entrez, Accession No. AAK28396, Chaudhary, D. and Long A.J. (Apr. 2, 2001).
NCBI Entrez, Accession No. Q9NS68, Eby, M.T., et al. (May 30, 2002).
NCBI Entrez, Accession No. NM—148957, Clark, H.F., et al. (Sep. 20, 2002).
NCBI Entrez, Accession No. AY358888, Clark, H.F., et al. (Oct. 1, 2003).
NCBI Entrez, Accession No. CAH70838, Pearce, A. (Nov. 9, 2004).
NCBI Entrez, Accession No. BC047321, Strausberg, R.L., et al. (Mar. 3, 2003).
NCBI Entrez, Accession No. AAF71828, Eby, M.T., et al. (May 25, 2000).
Brenner SE., “Errors in Genome Annotation,”Trends in Genetics15:132-133, Elsevier Science Ltd. (Apr. 1999).
Bork, et al., “Go Hunting in Sequence Databases But Watch Out for the Traps,”Trends in Genetics12:425-427, Elsevier Science Ltd. (Oct. 1996.).
Aggarwal et al., “Tumor Necrosis Factors: Developments During the Last Decade,”Eur. Cytokine Netw, 7:93-124, John Libbey Eurotext, Ltd. (1996).
Bazzoni et al., “The Tumor Necrosis Factor Ligand and Receptor Families,”N Engl. J. Med., 334:1717-1725, Massachusetts Medical Society (1996).
Bork, “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,”Genome Res.10:398-400, Cold Spring Harbor Laboratory Press (2000).
Eason et al., “Evaluation of Recombinant Human Soluble Dimeric Tumor Necrosis Factor Receptor for Prevention of OKT3-associated Acute Clinical Syndrome,”Transplantation, 61:224-228, Lippincott Williams & Wilkins (1996).
Eggermont et al., “Isolated Limb Perfusion with High-Dose Tumor Necrosis Factor-Alpha in Combination with Interferon-Gamma and Melphalan for Nonresectable Extremity Soft Tissue Sarcomas: A Multicenter Trial,”J. Clin. Oncol., 14:2653-2665, American Society of Clinical Oncology (1996).
Feldmann et al., “Role of Cytokines in Rheumatoid Arthritis,”Rev. Immunol., 14:397-440, Elsevier Science Ltd. (1996).
Green et al., “Fas-Ligand: Privilege and Peril.,”Proc. Natl. Acad. Sci. USA, 94:5986-5990, National Academy of Sciences (1997).
Mikayama et al., “Molecular Cloning and Functional Expression of a Cdna Encoding Glycosylation-Inhibiting Factor,”Proc. Natl. Acad. Sci. USA, 90:10056-10060, National Academy of Sciences (1993).
Skolnick et al., “From Genes to Proteins Structure and Function: Novel Applications of Computational Approaches in the Genomic Area,”Trends Biotechnol., 18:34-39, Elsevier Science Ltd. (2000).
Smith, “Virus Strategies for Evasion of the Host Response to Infection,”Trends Microbiol., 2:81-88, Elsevier Science Ltd. (1994).
Smith et al., “CD30 Antigen, a marker for Hodgkin's Lymphoma, is a Receptor Whose Ligand Defines an Emerging Family of Cytokines with Homology to TNF,”Cell, 73:1349-1360, Cell Press (1993).
Smith et al., “The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Costimulation, and Death,”Cell, 76:959-962, Cell Press (1994).
Van Dullemen et al., “Treatment of Crohn's Disease with Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2),”Gastroenterology, 109:129-135, W.B. Saunders (1995).
Doerks, T., et al., “Protein Annotation: Detective Work for Function Prediction,”Trends in Genetics14:248-250, Elsevier Science Ltd. (1998).
Smith, T.F., et al., “The Challenges of Genome Sequence Annotation or the Devil is in the Details,” 15:1222-1223Nature Publishing Group(1997).
Hession Catherine
Tschopp Jurg
Apoxis S.A.
Biogen Idec MA Inc.
Landsman Robert
Stern, Kessler, Goldstein & Fox P.L.L.C.
LandOfFree
TRAIN-R: a cysteine-rich member of the TNF-receptor family does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with TRAIN-R: a cysteine-rich member of the TNF-receptor family, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TRAIN-R: a cysteine-rich member of the TNF-receptor family will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2768628